News for Accelerate Diagnostics, Inc. (AXDX)

ARMISTICE CAPITAL, LLC (Trades, Portfolio), a notable investment firm, recently adjusted its position in Accelerate Diagnostics Inc (AXDX) by reducing its stake

Transaction Overview On February 4, 2025, Indaba Capital Management, L.P. (Trades, Portfolio) made a strategic move by acquiring 2,751,762 shares of Accelerate

PR NewswireTUCSON, Ariz., Jan. 10, 2025 TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! The ...

Tuesday's Top Insider Moves: Execs Buy and Sell Big in US Stocks

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsLaura Pierson - Investor...

Net Sales: Approximately $3 million for the quarter, compared to $3.3 million in the same period last year.Gross Margin: Approximately 29% for the quarter, up

Nov 07, 2024 / 09:30PM GMTOperator Good day, and welcome to the Accelerate Diagnostics, Inc., third-quarter 2024 earnings conference call. (Operator Instruction

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -25.53% and 0.83%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Net Sales: Approximately $3 million for Q2 2024, compared to $2.9 million in the same period of the prior year.Gross Margin: Approximately 23% for the quarter,

Aug 08, 2024 / 08:30PM GMTOperator Good day and welcome to the Accelerate Diagnostics Incorporated second quarter 2024 results conference call. (Operator Instru

Chicago, April 16, 2024 (GLOBE NEWSWIRE) -- In Vitro Diagnostics market in terms of revenue was estimated to be worth $85.2 billion in 2024 and is poised...

/PRNewswire/ -- The

Gainers YS Biopharma Co., Ltd. (NASDAQ: YS) shares rose 90.3% to $2.36 in pre-market trading after dropping over 7% on Monday. YS Biopharma's PIKA Rabies Vaccine recently received Phase 3 clinical trial approval from Philippines FDA.

/PRNewswire/ -- The

/PRNewswire/ -- The "Global Antimicrobial Susceptibility Testing Market (2022-2027) by Product, Type, Applications, Methods, End Users, Geography, Competitive...

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.

/PRNewswire/ -- According to Coherent Market Insights, the global antimicrobial susceptibility testing market is estimated to be valued at US$ 3,525.75 million...

Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company.